[The results of conservative treatment of oxalate urolithiasis in children].
Hyperoxaluria is defined as urinary oxalate excretion exceeding 0.45 mmol/1.73 m2/day and accounts for 15% of recurrent urolithiasis. There have been only a few reports on the prevalence and treatment of oxalate urolithiasis in children.


OBJECTIVE
Of the study was to assess the efficacy and safety of the protocol of intensive and combined treatment of hyperoxaluria in children.


METHODS
Seventeen children at the mean age of 11.5 +/- 4.5 years with positive history of urolithiasis and diagnosis of hyperoxaluria were studied. In this group hyperoxaluria was an isolated defect in 9 of 17 children, but in 3/17 it was accompanied by hyperuricosuria, in 5/17 by hypomagnesuria and in 1 case by hypercalciuria. During the 12-month period the children were intensively hydrated and received a low-oxalate diet and supplemental therapy with vitamin B6, magnesium, citrates and lactic acid bacteria preparations.


RESULTS
In all but one child oxaluria decreased below 0.45 mmol/1.73 m2/day (decrease by 45%). No new stone formation was seen during the observation period. In all patients abdominal pain and haematuria subsided.


CONCLUSIONS
We conclude that the intensive, complex, conservative treatment of hyperoxaluria in children is effective and safe. It allows to decrease hyperoxaluria and prevent the recurrence of urolithiasis.
Klinika Nefrologii i Dializoterapii Instytutu Centrum Zdrowia Matki Polki w Łodzi.
Anna
A
Rogowska-Kalisz
Marcin
M
Tkaczyk
Wiesława
W
Bilińska
Michał
M
Nowicki
D000293:Adolescent; D002648:Child; D002951:Citrates / Q000627:therapeutic use*; D005227:Fatty Acids / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006959:Hyperoxaluria / Q000188:drug therapy / Q000517:prevention & control / Q000652:urine; D008277:Magnesium Oxide / Q000097:blood; D008297:Male; D010070:Oxalates / Q000652:urine*; D014545:Urinary Calculi / Q000188:drug therapy* / Q000517:prevention & control / Q000652:urine*; D025101:Vitamin B 6 / Q000627:therapeutic use*
D002951:Citrates; D005227:Fatty Acids; D010070:Oxalates; D008277:Magnesium Oxide; D025101:Vitamin B 6; C028716:phytomonic acid